HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for head and neck cancer: experimental drug SI-B001 tested
Disease control OngoingThis study tests an experimental drug called SI-B001 in 11 adults with advanced head and neck cancer that has spread or returned after standard treatments like chemotherapy and immunotherapy. The goal is to see if the drug can shrink tumors and how safe it is. Participants receiv…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New immunotherapy cocktail aims to Re-Energize immune system against tough cancers
Disease control OngoingThis study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Immunotherapy may replace chemo in head and neck cancer treatment
Disease control OngoingThis study compares two treatments for advanced head and neck cancer: the immunotherapy drug pembrolizumab (Keytruda) plus radiation versus standard chemotherapy (cisplatin) plus radiation. About 126 participants with p16-positive cancer will be enrolled. The goal is to see if th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated May 26, 2026 04:09 UTC
-
New immunotherapy cocktail targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 04:09 UTC
-
New drug combo shows promise shrinking tumors before surgery
Disease control OngoingThis study tests whether giving the drug cemiplimab (alone or with another drug called fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the treatment and then have surgery. Researchers will check how …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New combo attack shows promise for Drug-Resistant cancers
Disease control OngoingThis study tests a new combination of three treatments—an immune-boosting injection (IL-2), targeted radiation, and the immunotherapy drug pembrolizumab—in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New drug RPH-002 takes on erbitux in head and neck cancer showdown
Disease control OngoingThis study tests whether a new drug called RPH-002 works as well as the standard drug Erbitux for people with advanced head and neck cancer that has spread or come back. About 161 participants will receive either RPH-002 or Erbitux, both combined with chemotherapy. The main goal …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New antibody takes aim at two cancer drivers in advanced tumors
Disease control OngoingThis study tests an experimental drug called MCLA-129 in people with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c-MET) at…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether giving a short course of immunotherapy (pembrolizumab) plus targeted radiation before surgery can shrink advanced head and neck cancers. The trial includes 28 adults with stage III or IVA HPV-negative head and neck squamous cell carcinoma. The main goal i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New cocktail shows promise for incurable head and neck cancer
Disease control OngoingThis study tests a three-drug combination (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants have advanced or r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New hope for head and neck cancer patients who failed standard treatment
Disease control OngoingThis study tests a new combination of drugs (LVGN6051, toripalimab, and paclitaxel) in 64 adults with advanced head and neck cancer that came back or spread after platinum-based treatment. The goal is to see if the combination is safe and shrinks tumors. Participants must be 18 o…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug combo aims to boost immunotherapy in hard-to-treat cancers
Disease control OngoingThis study tests a new drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab+ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests two different schedules of the experimental drug FID-007 combined with cetuximab in 46 adults with advanced head and neck cancer that has come back or spread. The goal is to see if the combo can shrink tumors and control the disease. Participants must have alread…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for head and neck cancer: drug combo shows promise in early trial
Disease control OngoingThis study tests a new drug called SI-B001 combined with paclitaxel in 42 adults with head and neck cancer that has returned or spread. Participants had already tried standard treatments. The goal is to see if the combination shrinks tumors and is safe. This is an early-phase tri…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
HPV vaccine combo shows promise against head and neck cancer
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control OngoingThis study tests whether combining three different medicines can shrink tumors in adults with head and neck cancer that has spread or come back. Participants are randomly assigned to receive different combinations of the study drugs as infusions. The goal is to see if these combi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New triple therapy aims to control advanced head and neck cancer
Disease control OngoingThis early-phase study tests a new drug (INCB081776) combined with standard radiation and an immunotherapy (pembrolizumab) in people with head and neck cancer that has come back or spread. The goal is to see if the combination is safe and helps control the disease. About 10 parti…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
Head and neck cancer patients: which chemo combo works best?
Disease control OngoingThis study compares two different chemotherapy drug combinations to find out which is more effective for treating advanced head and neck cancer that has not been treated before. About 128 adults with stage IV cancer of the throat, mouth, or voice box will be randomly assigned to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New drug combo aims to boost radiation for head and neck cancer
Disease control OngoingThis early-stage trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and check for side…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:51 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a new drug called sEphB4-HSA combined with standard chemotherapy in 61 people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The goal was to find the best dose and check for side effects. Whi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control OngoingThis study tests whether adding other drugs to tislelizumab can shrink tumors or slow cancer growth in people with advanced head and neck cancer that has come back or spread. About 160 adults whose cancer cannot be cured with local treatments will receive the drug combination as …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New drug combo aims to keep head and neck cancer at bay
Disease control OngoingThis study looks at whether adding lenvatinib to pembrolizumab after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with PD-L1 positive advanced cancer will receive either the combination or pembrolizumab alone. The goal is to see …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Cancer combo study pulled before it started
Disease control TerminatedThis study was designed to test a combination of two drugs (TTI-101 and pembrolizumab) in people with head and neck cancer that had come back or spread. The goal was to see if the combo was safe and could shrink tumors. However, the study was withdrawn before any participants wer…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Voice Box-Saving cancer trial: which chemo timing works best?
Disease control OngoingThis study compares two treatment plans for people with advanced larynx or hypopharynx cancer to see which better preserves the voice box without needing surgery. One group gets chemotherapy before radiation, the other gets chemo during radiation. The goal is to keep the larynx w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New cell therapy takes on hard-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New immunotherapy combo shows promise in head and neck cancer trial
Disease control OngoingThis study tests whether giving two immunotherapy drugs together before surgery is safe and practical for people with head and neck cancer. The drugs aim to boost the immune system to fight the tumor. About 24 participants will receive the treatment before their planned surgery, …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Diabetes drug plus immunotherapy shows promise against tough cancer
Disease control OngoingThis study tests whether adding the diabetes drug metformin to the immunotherapy pembrolizumab can help shrink tumors in people with advanced head and neck cancer that has spread. The trial enrolled 21 adults whose cancer could not be cured with surgery or radiation. Researchers …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New hope for tough cancers: SKB264 trial targets tumors resistant to standard care
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors (like lung, breast, or ovarian cancer) that have not improved with standard treatments. The goal is to find the best dose and see if it can shrink tumors. About 1,410 participants will receive the drug…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New combo therapy aims to boost quality of life in advanced head and neck cancer
Disease control OngoingThis study looks at adults with head and neck cancer that has spread to a few other spots (up to 3). It compares stereotactic radiotherapy alone versus radiotherapy plus chemotherapy. The goal is to see which approach helps patients live longer with a good quality of life and few…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New drug aims to shrink hard-to-treat cancers
Disease control OngoingThis early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Immunotherapy plus chemo shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can better shrink advanced head and neck cancer. About 122 people with resectable stage III or IV cancer will be randomly assigned to get either the combo or chemo alone fo…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with head and neck cancer that has come back or spread. About 52 adults with incurable, advanced cancer will take part. The goal is to s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New antibody drug shows promise in early cancer trial
Disease control OngoingThis early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New combo therapy aims to shrink head and neck tumors in phase 2 trial
Disease control OngoingThis study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or returned and cannot be cur…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New drug duo aims to boost immune attack on head and neck tumors before surgery
Disease control OngoingThis early-phase study tests two experimental drugs (LVGN7409 and LVGN3616) given together before surgery in 27 adults with HPV-negative head and neck cancer. The goal is to see if the combination is safe and can activate the immune system to fight the tumor. Participants receive…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New drug candidate ABBV-400 takes on eight tough cancers
Disease control OngoingThis early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo therapy aims to shrink hard-to-treat head and neck tumors
Disease control OngoingThis study tests a new drug called NT219 combined with either pembrolizumab or cetuximab in people with head and neck cancer that has come back or spread. The goal is to see if the combination can shrink tumors. About 29 adults with incurable head and neck squamous cell carcinoma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Triple threat: vaccine, immunotherapy, and Chemo-Radiation take on HPV head and neck cancer
Disease control OngoingThis study tests a new treatment for a type of head and neck cancer caused by HPV. It combines a vaccine that targets the cancer cells, an immunotherapy drug (pembrolizumab), and standard chemo-radiation. The goal is to see if this combination can better control the cancer and pr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 04, 2026 16:20 UTC
-
New three-step combo therapy targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not linked to HPV. First, patients receive a drug called palbociclib before standard chemoradiation, then they get more palbociclib after treatment. The goal is to see if this approach hel…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New Light-Based scanner aims to spot hidden cancer in neck nodes
Diagnosis TerminatedThis study is testing a new imaging tool called MSOT that uses light and sound to create detailed pictures of neck lymph nodes in people with head and neck cancer. The goal is to see if it can more accurately find cancer that has spread to the lymph nodes and also detect tissue d…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated May 26, 2026 03:57 UTC
-
AI-Powered watchdog aims to keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using a machine learning program to closely monitor symptoms can help head and neck cancer patients avoid urgent hospital visits during radiation therapy. About 72 adults with non-spreading head and neck cancer will either receive standard care or extra s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated May 18, 2026 11:59 UTC
-
Does more frequent Check-Ups after head and neck cancer save lives?
Knowledge-focused OngoingThis study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to the usual schedule. It includes 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. Participants are…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated May 26, 2026 04:11 UTC
-
3D tumor maps could sharpen radiation targeting in head and neck cancer
Knowledge-focused OngoingThis study tests whether creating a 3D map of a patient's tumor after surgery helps doctors plan radiation therapy more precisely. About 13 adults with head and neck cancer will have standard radiation, but researchers will also create a virtual 3D map to see if it changes the tr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated May 26, 2026 04:06 UTC
-
Cancer test study pulled before it even started
Knowledge-focused TerminatedThis study planned to check if a special test (OncoPrism-HNSCC) could predict how well immunotherapy would work in people with head and neck cancer. Researchers wanted to compare the test's accuracy to standard methods. However, the study was withdrawn before enrolling any partic…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Cofactor Genomics, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 03:52 UTC